Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Double-blinded, Randomized, Placebo-controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of a Topical Application of DLX105 Onto Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris

NCT01936337 is registered in ClinicalTrials.gov with Delenex Therapeutics AG as lead sponsor.

NCT NCT01936337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01936337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Double-blinded, Randomized, Placebo-controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of a Topical Application of DLX105 Onto Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris
Lead sponsor
Delenex Therapeutics AG
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2013
Completion date
July 31, 2014
Enrollment
59 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis vulgaris